|
|
Volumn 2, Issue 4, 2002, Pages 310-316
|
|
Parkinson's disease: medical treatment of moderate to advanced disease.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMANTADINE;
ANTIDEPRESSANT AGENT;
ANTIPARKINSON AGENT;
ANXIOLYTIC AGENT;
CATECHOL METHYLTRANSFERASE;
CHOLINERGIC RECEPTOR BLOCKING AGENT;
DOPAMINE RECEPTOR STIMULATING AGENT;
LEVODOPA;
NEUROLEPTIC AGENT;
NEUROPROTECTIVE AGENT;
COGNITIVE DEFECT;
DISEASE COURSE;
DRUG ANTAGONISM;
HUMAN;
PARKINSON DISEASE;
PATHOPHYSIOLOGY;
REVIEW;
AMANTADINE;
ANTI-ANXIETY AGENTS;
ANTIDEPRESSIVE AGENTS;
ANTIPARKINSON AGENTS;
ANTIPSYCHOTIC AGENTS;
CATECHOL O-METHYLTRANSFERASE;
CHOLINERGIC ANTAGONISTS;
COGNITION DISORDERS;
DISEASE PROGRESSION;
DOPAMINE AGONISTS;
HUMANS;
LEVODOPA;
NEUROPROTECTIVE AGENTS;
PARKINSON DISEASE;
|
|
EID: 0036654490
PISSN: 15284042
EISSN: None
Source Type: Journal
DOI: 10.1007/s11910-002-0006-5 Document Type: Review |
|
Times cited : (29)
|
|
References (58)
|
